Revolution Medicines, Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q4 2024). Net income: −$1.77B, trailing twelve months to Q2 2026. Free cash flow: −$1.23B, trailing twelve months to Q2 2026. EPS: −$8.85, trailing twelve months to Q2 2026.

RVMDRevolution Medicines, Inc.

Healthcare

$189.76+336% 1Y

$189.76

$42.5152 weeks$216.19

RVMD as reported

Revolution Medicines, Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied

Net income: −$1.77B
Net income · +118% year on year · trailing twelve months to Q2 2026
Free cash flow: −$1.23B
Free cash flow · +76% year on year · trailing twelve months to Q2 2026
EPS: −$8.85
EPS · +96% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RVMD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	n/a	Q4 2024 · 6 quarters behind
Net income	−$1.77B	+118%	Q2 2026
EPS	−$8.85	+96%	Q2 2026
Operating margin	−1650%	n/a	Q2 2023 · 12 quarters behind
Net margin	−1524%	n/a	Q2 2023 · 12 quarters behind
ROE	−72%	n/a	Q2 2026
ROA	−48%	n/a	Q2 2026
Free cash flow	−$1.23B	+76%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.